� LYDALL, INC. (NYSE: LDL) Charter Medical Ltd., a subsidiary of Lydall, Inc., has announced a breakthrough Bio-Container that utilizes an innovative new film technology. FREEZE-PAK� Bio-Containers are designed for use in cryogenic temperature applications providing robust carrying out as low as -196�C and continue flexible in a frozen state.
FREEZE-PAK� offers advantages over traditional Bio-Containers as it goes down to the lowest temperature ambit while also providing easy storage of materials in a pre-sterilized format. They are available in a range of configurations to fit a variety of freezing systems. FREEZE-PAK� Bio-Containers are intentional for maximum product recovery, constructed of animal derivative-free materials and conform to current industry standards.
According to Roberta Morris, Director of Marketing and New Product Development at Charter Medical, "Storage of cellular products is typically performed under cryogenic conditions, with the singular construction of FREEZE-PAK� a much lower temperature grasp is achieved compared to typical Bio-Containers which are generally limited to -80�C."
Charter Medical Ltd., a subsidiary of Lydall, Inc., is headquartered in Winston-Salem, North Carolina. Learn more at hypertext transfer protocol://www.chartermedical.com.
Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, and Germany and sales offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical and filtration/separation markets. Charter Medical's Vital Fluid business enterprise serves the life science industry with custom-engineered solutions for bloodline transfusion and medical gimmick applications. Charter Medical manufactures Bio-Pak� single-use Bio-Containers of media, buffers and mass intermediates in Biotech, Pharmaceutical and Diagnostic reagent manufacture processes.
Charter Medical Ltd.
More info
